ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
BiomX Inc

BiomX Inc (PHGE)

0.5086
0.0406
(8.68%)
0.51
0.0014
(0.28%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.51
Bid
-
Ask
-
Volume
306,364
0.468 Day's Range 0.51
0.34 52 Week Range 3.864
Market Cap
Previous Close
0.468
Open
0.50
Last Trade
100
@
0.5086
Last Trade Time
Financial Volume
$ 152,657
VWAP
0.498286
Average Volume (3m)
186,664
Shares Outstanding
26,176,311
Dividend Yield
-
PE Ratio
-0.75
Earnings Per Share (EPS)
-0.68
Revenue
-
Net Profit
-17.73M

About BiomX Inc

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflamma... BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Show more

Sector
Blank Checks
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Dover, Delaware, USA
Founded
2017
BiomX Inc is listed in the Blank Checks sector of the American Stock Exchange with ticker PHGE. The last closing price for BiomX was $0.47. Over the last year, BiomX shares have traded in a share price range of $ 0.34 to $ 3.864.

BiomX currently has 26,176,311 shares outstanding. The market capitalization of BiomX is $12.25 million. BiomX has a price to earnings ratio (PE ratio) of -0.75.

PHGE Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0715.90909090910.440.510.347182480.45518198CS
4-0.01-1.923076923080.520.56740.342865970.46352899CS
12-0.04-7.272727272730.550.70.341866640.5190699CS
26-0.0566-9.989410518880.56661.16090.341363180.59319653CS
52-2.824-84.70305938813.3343.8640.341587601.22554711CS
156-5.99-92.15384615386.511.70.344004985.08399929CS
260-59.39-99.148580968359.990.4950.342565977.41445714CS

PHGE - Frequently Asked Questions (FAQ)

What is the current BiomX share price?
The current share price of BiomX is $ 0.51
How many BiomX shares are in issue?
BiomX has 26,176,311 shares in issue
What is the market cap of BiomX?
The market capitalisation of BiomX is USD 12.25M
What is the 1 year trading range for BiomX share price?
BiomX has traded in the range of $ 0.34 to $ 3.864 during the past year
What is the PE ratio of BiomX?
The price to earnings ratio of BiomX is -0.75
What is the reporting currency for BiomX?
BiomX reports financial results in USD
What is the latest annual profit for BiomX?
The latest annual profit of BiomX is USD -17.73M
What is the registered address of BiomX?
The registered address for BiomX is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the BiomX website address?
The website address for BiomX is www.biomx.com
Which industry sector does BiomX operate in?
BiomX operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AIMAIM ImmunoTech Inc
$ 9.3008
(9,700.63%)
87.17k
MITQMoving iMage Technologies Inc
$ 0.82
(48.26%)
190.7M
SYNXSilynxcom Ltd
$ 2.07
(21.76%)
818.13k
GNSGenius Group Limited
$ 0.5408
(20.71%)
66.94M
MPUMega Matrix Inc
$ 1.07
(20.22%)
711.94k
HUSAHouston American Energy Corp
$ 14.85
(-15.14%)
2.13M
RYDERyde Group Ltd
$ 0.388
(-13.78%)
11.7M
MXCMexco Energy Corp
$ 11.3961
(-13.07%)
35.33k
RODEHartford Multifactor Diversified International ETF
$ 27.57
(-12.81%)
218
CVRChicago Rivet and Machine Co
$ 11.8801
(-12.00%)
3.73k
MITQMoving iMage Technologies Inc
$ 0.82
(48.26%)
190.7M
DNNDenison Mines Corp
$ 1.73
(-5.98%)
171.46M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 21.21
(-1.85%)
137.08M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
$ 9.54
(2.03%)
133.55M
SPYSPDR S&P 500
$ 594.28
(-0.53%)
94.05M

PHGE Discussion

View Posts
glenn1919 glenn1919 4 months ago
PHGE..............https://stockcharts.com/h-sc/ui?s=PHGE&p=W&b=5&g=0&id=p86431144783
👍️0
BurgerKing82 BurgerKing82 6 months ago
Potential here?
👍️0
glenn1919 glenn1919 7 months ago
PHGE.............................https://stockcharts.com/h-sc/ui?s=PHGE&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 10 months ago
PHGE...POST SPLIT BLITZ
👍️0
TMEvans TMEvans 12 months ago
Has anyone compared what we're doing at PHGE with what they're doing at Cytophage? (TSX-V:CYTO)... Those guys seem to be commercializing a phage product.... I'm excited for the prospects of the whole industry. The 'Age of Phage' is upon us!
👍️0
Stumblebum Stumblebum 12 months ago
Just got my proxy vote info…..they ask that we approve increase in shares from 120m to 750m…..then a few questions down they ask for approval for a rs somewere between 1-5 to 1-0 within the next year….duh
👍️0
DOGONE DOGONE 1 year ago
Presentation of Merger.

https://www.otcmarkets.com/filing/html?id=17345766&guid=wxd-kWz4RHzKJth#ea0201229ex99-3_biomx_htm

Here is slide 4

👍️0
TheFinalCD TheFinalCD 1 year ago
https://ih.advfn.com/stock-market/AMEX/biomx-PHGE/stock-news/93434738/form-8-k-current-report
👍️0
subslover subslover 1 year ago
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the treatment of diabetic foot osteomyelitis (“DFO”)

Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive agreement for a private placement financing of $50 million that will be used to advance two lead product candidates through Phase 2 clinical readouts in 2025

Conference call today at 9:00 a.m. EST

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections (the “Acquisition”). Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of BiomX will own approximately 55% and the former stockholders of APT will own approximately 45% of the consolidated entity of BiomX and APT. The Acquisition is expected to close within the next 30 days, subject to the satisfaction of the closing conditions described in the definitive merger agreement. Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive purchase agreement for the sale of shares of newly created non-voting convertible preferred stock (“Series X Preferred Stock”) and warrants to purchase shares of BiomX common stock in a private placement to certain institutional accredited investors led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital. The private placement is expected to result in gross proceeds to BiomX of $50 million before deducting placement agent and other offering expenses. The proceeds from the private placement are expected to provide funding through the results from a planned Phase 2b trial that will evaluate BiomX’s lead product candidate, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (P. aeruginosa) in CF patients expected in the third quarter of 2025 and Phase 2 results from APT’s clinical-stage product candidate, now named BX211, for the treatment of Staphylococcus aureus (S. aureus) infections in DFO patients expected in the first quarter of 2025. The private placement is expected to close substantially concurrently with, and subject to the closing of, the Acquisition.

“BiomX’s acquisition of APT will create a leading phage company with diverse technologies and an advanced clinical pipeline,” said Jonathan Leff, Partner and Chairman of the Deerfield Institute at Deerfield Management. “With important data readouts for two programs expected in 2025, the funding from this transaction is designed to provide multiple opportunities to create stockholder value by reaching critical inflection points in each program’s clinical development.”

“Today’s announcement sends a clear vote of confidence from leading biotechnology investors who led this transaction that phage technology holds significant potential to treat serious infections with significant unmet need and limited treatment options,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In the case of CF, BX004 has the potential to improve lung function in patients with chronic and potentially deadly pulmonary infections.”

“APT’s phage therapy for DFO holds the potential to prevent amputations associated with intractable infections that have penetrated into the bone in patients with diabetic foot ulcers,” said Greg Merril, Founder and Board Director of APT. “With the combined intellectual and financial resources coming from this acquisition, we now have a clear line of sight towards applying this ground-breaking technology to reach multiple data readouts in CF and DFO over the next 12-24 months.”

Management and Organization
BiomX will continue to be led by its current management team, with the addition of Michael Billard from APT as General Manager, U.S. Following the transaction, the BiomX board of directors will be comprised of Dr. Russell Greig, Chair of the Board of Directors, and the following members of the board of directors - Dr. Jesse Goodman, Jonathan Leff, Dr. Alan Moses, Greg Merril, Eddie Williams and Jonathan Solomon, BiomX’s Chief Executive Officer.

About the Acquisition and the Private Placement

The Acquisition is structured as a stock-for-stock transaction whereby all outstanding equity interests of APT will be exchanged in a merger for 9,164,967 shares of BiomX common stock, 40,471 shares of Series X Preferred Stock convertible into 40,471,000 shares of BiomX common stock and warrants (“Merger Warrants”) exercisable for 2,166,497 shares of BiomX common stock. Following the consummation of the Acquisition, a successor-in-interest of APT will become a wholly-owned subsidiary of BiomX. The Merger Warrants will be exercisable at any time after the date of the receipt of stockholder approval at an exercise price of $5.00 per share and will expire on January 28, 2027. The definitive merger agreement is subject to various closing conditions, including, among other conditions, receiving cash of not less than $50 million from the private placement.

Concurrently with the entry into the definitive merger agreement with APT, BiomX entered into a definitive purchase agreement for a private placement investment with existing and new investors to raise $50 million, in which the investors have agreed to purchase (i) an aggregate of 216,417 shares of Series X Preferred Stock and (ii) warrants (“Private Placement Warrants”) to purchase up to an aggregate of 108,208,500 shares of BiomX common stock, at a combined purchase price of $231.10 per share of Series X Preferred Stock and an accompanying Private Placement Warrant to purchase 500 shares of common stock. The Private Placement Warrants w
👍️ 1
Triple nickle Triple nickle 2 years ago
Hmmmm insider sellin at .40
👍️0
makinezmoney makinezmoney 4 years ago
$PHGE: Agreement with Maruho for Atopic Dermatitis Product Candidate BX005


Now at $3




GO $PHGE
👍️0

Your Recent History

Delayed Upgrade Clock